** BCAL Diagnostics BDX.AX jumps as much as 9.1% to A$0.12, highest since February 24
** Diagnostics firm gets national ethics approval in Australia for a registry study on up to 24,000 women where subjects will use co's breast cancer screening product BREASTESTplus as part of their clinical treatment
** CEO says registry will accelerate doctor adoption while collecting real-world data to support future reimbursement
** YTD, BDX gains 13.4%
(Reporting by Shruti Agarwal in Bengaluru)
((Shruti.Agarwal@thomsonreuters.com))